$AZN - AstraZeneca Receives Two U.S. FDA Approvals, Including Expanded Use of Imfinzi and a New Treatment for a Rare Disease
107
Tim Carmichael retweeted
Less than a year ago, DOGE cut 400 jobs at the already understaffed FAA. At the time, FAA employees said the cuts would "have long-term safety implications." Looks like they were right. apnews.com/article/faa-firin…
$TGTX next meaningful stock trigger —- BRIUMVI SubQ data readout —- is just around the corner. This data could lead to higher revenue targets and blast the 30 million shares SOLD SHORT into covering their $$ losing negative bets🚀🚀🚀
$TGTX OW -JP catch up MGT -comments on next meaningful leg of BRIUMVI story -SUBq on track readout YE/early next year - trial has passed time points to collect 6 month PK endpoint for all 360 patients - data cleaning underway
$QURE high risk/ high reward — nothing available to patients with the deadly Huntingtons Disease. Risk/reward could be very positive over the next 6 months💥💥💥
Mr. Diamantas, the FDA Commissioner, literally telling you the vibes at the FDA. If you don't think $QURE isn't getting approved you've lost the plot.
5
818
CRWV Stock Eyes Biggest One-Day Gain Since August — Citi Sees Over 200% Upside After Q3 Beat
stocktwits.com/news-articles… $CRWV
94
$TGTX new 52 week high — 30 million shares SOLD SHORT. Must be getting a little hot under the collar betting that the strong fundamentals & technicals are going away🔥🔥🔥🔥🔥
TG Therapeutics’ CEO Sees Global Revenue Exceeding $1B In 2026 – BRIUMVI Drives Q3 Topline Beat
stocktwits.com/news-articles… $TGTX
1
21
650
$TGTX Jeffries like the story — PT $83
$TGTX Jefferies PT $83 SUBq on track &Commercial trends remain strong, w/ new pt starts accelerating exiting 3Q &into 4Q, Oct marking a record month for total Briumvi prescribers, and persistence remaining above Co's expectations. Tx-naive pts now represent ~40% of new pt starts vs. ~25% at launch, while ~1/3 of starts come from pts switching from another CD20. Co also highlighted increasing adoption among younger women aged 18-40, likely driven by increase in new starts. Hospital penetration is improving, w/ Sept and Oct representing strongest hospital months since launch.
13
395
CRWV Rallies Ahead Of Quarterly Report: Wells Fargo Calls CoreWeave ‘Highest Quality’ Firm Among Neocloud Peers, Sees Upside
stocktwits.com/news-articles…. $CRWV
135
TG Therapeutics’ CEO Sees Global Revenue Exceeding $1B In 2026 – BRIUMVI Drives Q3 Topline Beat
stocktwits.com/news-articles… $TGTX
META, AMZN Stocks Jump As JPMorgan Picks Pair Over Alphabet — Sees Stronger AI Returns, Cloud Growth
stocktwits.com/news-articles… $AMZN $META
1
159
SPCX Stock Rises As SpaceX Advances $24B Texas Data Center And Gas Plant Plans
stocktwits.com/news-articles… $SPCX
168
$TGTX
Having been invested in $TGTX for the last 5 years I’ve seen how people get too anxious around Q earnings announcements. Having such a large short position —all with $ losing positions— and jittery retail traders looking for takeovers will do that.
The shorts did their best to drill the stock down to the low $50s and failed — as institutional investors added to positions cleaning out the shaky sellers.
$TGTX continues to be in an enviable position, raising revenue and earnings estimates — as they continue to take market share Q after Q.
The story remains very much on track and looks to be a favorable risk/reward from current levels. Look for new highs. 💥💥💥💥
$TGTX Q3 2026 Financial Results have been released! Details: bit.ly/4Ao3Szy - Join our #Earnings call TODAY, Mon., Nov. 9, 2026 @ 8:30AM ET. Dial in: 1-877-407-8029 (US), 1-201-689-8029 (Ex-US) Title: TG Q3 2026 – Webcast: ir.tgtherapeutics.com/events #FearlessForPatients
5
411
$CYTK solid Q results beating on top & bottom line. Look for Street numbers to be going up💥💥💥
3
391
Madrigal’s Rezdiffra storms past blockbuster milestone as CEO hails ‘accelerating’ MASH market fiercepharma.com/pharma/madr… $MDGL
355







